Serum transferrin as a predictor of prognosis for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma

Hepatology Research

Volumn 44, Issue 5, 2014, Pages 481-490

  Zaitsu, Junichi ^a   Yamasaki, Takahiro ^a   Saeki, Issei ^a   Harima, Yohei ^a   Iwamoto, Takuya ^a   Harima, Yumiko ^a   Matsumoto, Toshihiko ^a   Urata, Yohei ^a   Hidaka, Isao ^a   Marumoto, Yoshio ^a   Ishikawa, Tsuyoshi ^a   Takami, Taro ^a   Yamamoto, Naoki ^a   Kaino, Seiji ^a   Uchida, Koichi ^a   Terai, Shuji ^a   Sakaida, Isao ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced hepatocellular carcinoma; Hepatic arterial infusion chemotherapy; Iron; Prognostic predictor; Serum transferrin

Indexed keywords

ALPHA FETOPROTEIN; CISPLATIN; DECARBOXYPROTHROMBIN; FLUOROURACIL; FOLINATE CALCIUM; IMMUNOREACTIVE INSULIN; ONDANSETRON; PEGINTERFERON ALPHA2B; SERUM ALBUMIN; TRANSFERRIN;

ADULT; ADVANCED CANCER; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HEPATIC ARTERIAL INFUSION CHEMOTHERAPY; HUMAN; LIVER CELL CARCINOMA; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TRANSFERRIN BLOOD LEVEL; TREATMENT DURATION; TUMOR VOLUME;

EID: 84899087142     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12141     Document Type: Article

References (48)

1. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999; 341: 1986-1995.
2. Brodie C, Siriwardana G, Lucas J etal. Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of the cell cycle. Cancer Res 1993; 53: 3968-3975.
3. Le NT, Richardson DR. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta 2002; 1603: 31-46.
4. Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 2005; 57: 547-583.
5. Hann HW, Stahlhut MW, Rubin R, Maddrey WC. Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer 1992; 70: 25-26.
6. Kicic A, Chua AC, Baker E. Effect of iron chelators on proliferation and iron uptake in hepatoma cells. Cancer 2001; 92: 3093-3110.
7. Sakaida I, Hironaka K, Uchida K, Okita K. Iron chelator deferoxamine reduces preneoplastic lesions in liver induced by choline-deficient L-amino acid-defined diet in rats. Dig Dis Sci 1999; 44: 560-569.
8. Sakaida I, Kayano K, Wasaki S, Nagatomi A, Matsumura Y, Okita K. Protection against acetaminophen-induced liver injury in vivo by an iron chelator, deferoxamine. Scand J Gastroenterol 1995; 50: 61-67.
9. Jin H, Terai S, Sakaida I. The iron chelator deferoxamine causes activated hepatic stellate cells to become quiescent and to undergo apoptosis. J Gastroenterol 2007; 42: 475-484.
10. Yamasaki T, Terai S, Sakaida I. Deferoxamine for advanced hepatocellular carcinoma. N Engl J Med 2011; 365: 576-578.
11. Yu Y, Gutierrez E, Kovacevic Z etal. Iron chelators for the treatment of cancer. Curr Med Chem 2012; 19: 2689-2702.
12. Gkouvatsos K, Papanikolaou G, Pantopoulos K. Regulation of iron transport and the role of transferrin. Biochim Biophys Acta 2012; 1820: 188-202.
13. Stevens RG, Beasley RP, Blumberg BS. Iron-binding proteins and risk of cancer in Taiwan. J Natl Cancer Inst 1986; 76: 605-610.
14. Silber JH, Evans AE, Fridman M. Models to predict outcome from childhood neuroblastoma: the role of serum ferritin and tumor histology. Cancer Res 1991; 51: 1426-1433.
15. Okuda K, Ohtsuki T, Obata H etal. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 918-928.
16. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
17. Llovet JM, Di Bisceglie AM, Bruix J etal.; Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 1000: 698-711.
18. Arii S, Sata M, Sakamoto M etal. Management of hepatocellular carcinoma: report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010; 40: 667-685.
19. Urayama N, Yamasaki T, Harima Y etal. Hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: analysis of 114 cases. Kanzo 2011; 52: 449-460. (In Japanese with English abstract.)
20. Yamasaki T, Sakaida I. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma and future treatments for the poor responders. Hepatol Res 2012; 42: 340-348.
21. Yamasaki T, Kurokawa F, Shirahashi H etal. Novel arterial infusion chemotherapy using cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma. Hepatol Res 2002; 23: 7-17.
22. Yamasaki T, Kurokawa F, Takami T etal. Arterial infusion chemotherapy using cisplatin, 5-fluorouracil, and isovorin for patients with advanced hepatocellular carcinoma, pilot study: is a high dose of the biochemical modulator effective? Hepatol Res 2003; 27: 36-44.
23. Yamasaki T, Kimura T, Kurokawa F etal. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J Gastroenterol 2005; 40: 70-78.
24. Takaki-Hamabe S, Yamasaki T, Saeki I etal. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: is the addition of subcutaneous interferon-alpha-2b beneficial? Hepatol Res 2009; 39: 223-230.
25. Okita K, Yamasaki T, Hamabe S etal. Hepatic arterial infusion chemotherapy in combination with pegylated interferon-α-2b for advanced hepatocellular carcinoma. Hepatogastroenterology 2012; 59: 533-537.
26. Liver Cancer Study Group of Japan. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 5th edn. Tokyo: Kanehara, 2009. (In Japanese.)
27. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003; 38: 207-215.
28. Oken MM, Creech RH, Tormey DC etal. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
30. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649.
31. Obi S, Yoshida H, Toune R etal. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106: 1990-1997.
32. Nagano H, Wada H, Kobayashi S etal. Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. Oncology 2011; 80: 63-69.
33. Kim BK, Park JY, Choi HJ etal. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2011; 137: 659-667.
34. Uka K, Aikata H, Takaki S etal. Pretreatment predictor of response, time to progression, and survival to intraarterialb 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol 2007; 42: 845-853.
35. Park JY, Ahn SH, Yoon YJ etal. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007; 110: 129-137.
36. Niizeki T, Sumie S, Torimura T etal. Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy. J Gastroenterol 2012; 47: 686-695.
37. Ota H, Nagano H, Sakon M etal. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-α and intra-arterial 5-fluorouracil; role of type I interferon receptor expression. Br J Cancer 2005; 93: 557-564.
38. Kurokawa Y, Matoba R, Nagano H etal. Molecular prediction of response to 5-fluorouracil and interferon-α combination chemotherapy in advanced hepatocellular carcinoma. Clin Cancer Res 2004; 10: 6029-6038.
39. Qin LX, Tang ZY. The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol 2002; 8: 193-199.
40. op den Winkel M, Nagel D, Sappl J etal. Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. PLoS ONE 2012; 7: e45066.
41. Büyükaşik NS, Nadir I, Akin FE etal. Serum iron parameters in cirrhosis and chronic hepatitis: detailed description. Turk J Gastroenterol 2011; 22: 606-611.
42. McNamara L, MacPhail AP, Mondishona E etal. Non-transferrin-bound iron and hepatic dysfunction in African dietary iron overload. J Gastroenterol Hepatol 1999; 14: 126-132.
43. Takami T, Sakaida I. Iron regulation by hepatocytes and free radicals. J Clin Biochem Nutr 2011; 48: 103-106.
44. De Feo TM, Fargion S, Duca L etal. Non-transferrin-bound iron in alcohol abusers. Alcohol Clin Exp Res 2001; 25: 1494-1499.
45. Harrison P, Marwah SS, Hughes RT, Bareford D. Non-transferrin bound iron and neutropenia after cytotoxic chemotherapy. J Clin Pathol 1994; 47: 350-352.
46. Bradley SJ, Gosriwitana I, Srichairatanakool S, Hider RC, Porter JB. Non-transferrin-bound iron induced by myeloablative chemotherapy. Br J Haematol 1997; 99: 337-343.
47. Hu CT, Wu JR, Cheng CC etal. Reactive oxygen species-mediated PKC and integrin signaling promotes tumor progression of human hepatoma HepG2. Clin Exp Metastasis 2011; 28: 851-863.
48. Lu CL, Qiu JL, Huang PZ etal. NADPH oxidase DUOX1 and DUOX2 but not NOX4 are independent predictors in hepatocellular carcinoma after hepatectomy. Tumour Biol 2011; 32: 1173-1182.